A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

"We are pleased the FDA has accepted our NDA for Bumetanide Nasal Spray," said Benjamin Esque, CEO of Corstasis Therapeutics ...

The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it may ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression. Spravato was ...

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

People in Phoenix suffering from severe depression now have a Ketamine-derived nasal spray available for treatment.